Recommended as the better buy for 2026 due to superior performance across multiple timeframes (80.2% 1-year return, 20.6% 3-year return). Strong small-cap biotech exposure benefits from favorable market conditions, though higher volatility is acknowledged.
Suitable for aggressive investors seeking growth with strong 1-year returns (89.3%), but carries significant risks including high maximum drawdown (54%), higher expense ratio (0.35%), lower dividend yield (0.4%), and disappointing 5-year performance (~$1,154 on $1,000 invested).
XBI is presented as a viable alternative with specific merits and drawbacks. While it offers higher 1-year returns (62.20%) and targeted biotech exposure (151 holdings), it has higher expense ratio (0.35%), lower dividend yield (0.33%), significantly higher volatility (max drawdown -54.70%), and weaker 5-year performance. Suitable only for aggressive investors seeking biotech-specific exposure.
Articles that tag XBI but are mainly about other companies.
Listed as an alternative biotech ETF with $10.19 billion in assets and 0.35% expense ratio, comparable to BBH but no distinct advantages noted.
Referenced as a benchmark index showing broader biotech sector strength (+13.8% from May to July 2026), used to highlight Anavex's underperformance relative to the industry.
Mentioned as an alternative with the largest assets ($11.55 billion) among the three compared ETFs and the lowest expense ratio at 0.35%.
Biotech sector is up 39% year-to-date in 2026, beating tech and running even with energy, indicating strong sector momentum despite volatility.
Benefiting from M&A activity and patent-cliff pressure with improving risk appetite. Equal-weighted XBI shows better breadth than cap-weighted alternatives, though fundamentals remain mixed.
Highlighted as a strong investment vehicle with ~11% YTD returns outperforming S&P 500, diversified exposure across market caps, low 0.35% expense ratio, and positioned to benefit from patent cliff-driven M&A activity.
Mentioned as a diversified alternative for broader biotech exposure; no specific performance data or recommendation provided beyond being a sector option.
Quietly emerging as a contender, within earshot of 52-week highs on both absolute and relative basis to S&P 500. Appearing on SCTR reports with strong technical rank.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology